Prognostic immunoinflammatory and transcriptomic profiles in patients with pleural mesothelioma undergoing immunotherapy

Key Points

• Identifying prognostic biomarkers improves outcomes for patients receiving immunotherapy for pleural mesothelioma.
• The study emphasizes the importance of the tumor immune microenvironment and transcriptomic profiles in treatment efficacy.
• A multiscale approach combines immune-inflammatory metrics with tumor characteristics for more accurate prognostic insights.
• Findings suggest that monitoring these biomarkers may enhance personalized treatment strategies for advanced pleural mesothelioma.

Abstract